drug_type
RELEVANT_DRUG
intervention_type
Biological (DNA vaccine)
drug_description
A naked DNA plasmid vaccine (genetic immunotherapy) encoding the GPC3 antigen, administered intramuscularly with electroporation to induce GPC3-specific adaptive immune responses after radical resection of GPC3-positive hepatocellular carcinoma.
nci_thesaurus_concept_id
C202243
nci_thesaurus_definition
A plasmid DNA therapeutic cancer vaccine encoding glypican-3 (GPC3), with potential immunomodulating and antineoplastic activities. Upon intramuscular administration of GPC3-targeted plasmid DNA vaccine NWRD06 and following electroporation, the plasmids enter the cells, and the cells express GPC3 and elicit a GPC3-specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing GPC3. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed on normal, healthy cells; GPC3 plays an important role in cellular proliferation and differentiation.
drug_mesh_term
DNA Vaccines
drug_category
GENE THERAPY
drug_class
Vaccine
drug_delivery_route
Intramuscular
drug_mechanism_of_action
Intramuscular electroporation delivers a plasmid encoding glypican-3 (GPC3) into local cells, leading to in vivo GPC3 expression. The antigen is processed and presented by antigen-presenting cells via MHC I/II, priming GPC3-specific CD8+ cytotoxic and CD4+ helper T-cell responses that eliminate GPC3-positive hepatocellular carcinoma cells and support immune memory.
drug_name
NWRD06
nct_id_drug_ref
NCT06088459